Abzena

Headed to Milan for CPHI next week?  We invite you to join our exclusive evening networking reception, "Developability at the Duomo," on Tuesday, October 8th from 7-9pm. Relax after Day 1 of the conference with industry colleagues on the rooftop of Obicà Mozzarella Bar overlooking the stunning Milan Cathedral in the Piazza Duomo. This event offers the opportunity to unwind and share insights with peers, all while enjoying tasty beverages and appetizers. We hope to see you there!   Click here to register for the event: https://lnkd.in/ebUdxhGk   #CPHIWorldwide #DrugDevelopment #CDMO #CRO #Biopharma #Networking

Join us on October 8th at our San Diego cGMP manufacturing facility for a lunch seminar on bioassay strategies for successful IND submission. Dr Erika Kovacs, our Senior Director of Bioassay, will discuss critical considerations in developing stage-appropriate bioassays for complex biologics and bioconjugates, helping you accelerate and de-risk your development process.    Learn how selecting the right assays based on the development stage and mechanism of action can maximize your chances of clinical and commercial success.   Register for the seminar here: https://lnkd.in/g45kHX2C #DrugDevelopment #Bioassays #Biologics #Bioconjugates #INDSubmission #CDMO #CRO

New and existing technologies and a patient-centric focus are driving innovation in drug formulation. In the latest issue of Pharmaceutical Technology, Gary Watts, Head Of Formulation, discusses how factors like the desire to create new delivery methods for biologics, the need to increase patient adherence, and the integration of technologies such as artificial intelligence (AI) are pushing drug formulation in exciting directions.   Gary emphasizes: “The outsourcing partner should offer a broad range of formulation and manufacturing services that support a biopharmaceutical product throughout its entire lifecycle from the initial pre-formulation through to clinical trials and product launch.”     Read the full article to learn more about how innovation and a patient-centric approach are forging ahead in drug formulation. https://lnkd.in/efW3q2uX   #PharmaceuticalTechnology #DrugFormulation #Biopharma #PatientCentricity #CRO #DrugDevelopment #CDMO

Abzena is proud to be a sponsor of the upcoming PBSS workshop tomorrow in San Diego on DMPK/Clinical Pharmacology Studies for IND/NDA Filings. Our drug development experts, Parviz A. Shamlou, Eric Miller, and Craig Magee, Ph.D. will be there to discuss our expanded global capabilities.   From antibodies (mAbs) to recombinant vaccines and bioconjugates, we offer fully integrated, end-to-end services that support your drug development programs from discovery through commercial product launch. We invite you to attend the event and to explore how Abzena can help address your projects' unique challenges and accelerate your path to IND/NDA filings. Schedule a meeting with our team here: https://lnkd.in/e2kzmvKb   #PBSS #DrugDevelopment #DMPK #ClinicalPharmacology #CRO #Biopharmaceuticals #CDMO

Abzena's VP of Human Resources, Rob Watts FCIPD, spoke at the Cambridge Network HR Director's Dinner this week, discussing topics ranging from formulating a structured HR strategy across two continents, to the challenges of managing teams across multiple time zones. The conversation focused on the importance of aligning HR strategies with global business objectives to ensure seamless operations across regions.   This discussion demonstrates Abzena’s capability to manage global teams efficiently, addressing the unique challenges of operating across continents while maintaining alignment with organizational goals and company culture.   #Cambridge #HR #CompanyCulture #BusinessStrategy #CDMO #CRO

NEWS: We are thrilled to announce significant timeline and productivity enhancements to our mammalian cell line development platform, AbZelectPRO™. Now, biopharma customers can reach their research cell bank (RCB) in just 10 weeks, producing up to 8 g/L of high-performing titers before process development—a timeline reduction of over 30%.   The platform combines ProteoNic’s 2G UNic® vector technology with our host CHO cell line, resulting in a higher frequency of high-producing clones for therapeutic protein and recombinant vaccine production, including difficult-to-express proteins like bispecifics and fusion proteins.   Simon Keen, VP of Cell Line Development at Abzena, stated: “Over the past 10 months, we've been fine-tuning the platform, generating more data from real-world projects, which has allowed us to showcase its full potential and benefits to our customers. We are thrilled that AbZelectPRO™ has consistently demonstrated improved cycle times and productivity, giving our customers more shots on goal in achieving success in the clinic.”   Read the full press release here: https://lnkd.in/ea5eHHEu   #AbZelectPRO #CellLineDevelopment #Biopharma #DrugDevelopment #CDMO #CRO

Contract Pharma's latest CEO Spotlight, features Abzena's CEO, Matthew Stober, sharing his strategic vision for steering Abzena’s future growth, highlighting how broader CDMO industry trends influence his decisions.    As Matthew states, “Today, it is crucial for CDMOs to not only possess strong manufacturing capabilities but to have expertise in analytical development as well. One of the key differentiators of our company is that we perform all the analytical development and testing in-house. By having all the necessary tools and expertise, we can swiftly troubleshoot and resolve any issues that may arise on projects, ensuring our customers enjoy greater control and efficiency."   With over two decades of experience, Abzena is a leading integrated CDMO for antibody-drug conjugates (ADCs) and complex biologics, serving clients from early discovery through commercial launch.   Read the full article here: https://lnkd.in/eZv_vkHD   #CEOSpotlight #BiopharmaInnovation #CDMO #CRO #Bioconjugates #BiotechLeadership

Headed to the 23rd Annual Contract Pharma Conference this week? If so, make sure to swing by our table to connect with our drug development experts Austin McKinsey, Manager of Bioconjugation Process Development, Yang Wang-Smalley, Senior Director of Business Development and Michael Silberman, Manager of Client Engagement. Our team will be on hand to hear about your ADC or complex biologic and to discuss how Abzena can help assist in streamlining your program to its next target inflection point.   From early discovery through commercial product launch, our fully integrated drug development and cGMP manufacturing services can help turn your scientific discoveries into reality.  Schedule a meeting with our team here: https://lnkd.in/eXZfEhMR   #ContractPharma #BiopharmaInnovation #DrugDevelopment #Biopharmaceuticals #CDMO #PharmaConference #CRO

In the latest episode of the CPHI Podcast Series, Thomas A. Cornell, Senior Manager of Protein Engineering, joins host Lucy Chard to explore the pivotal role of protein engineering in biopharmaceutical drug design and development.    The discussion highlights how protein engineering enhances a drug products' stability, specificity, and functionality, particularly for antibody drugs. Key topics include the potential of bispecifics to improve drug functionality and the integration of genomics and AI to develop drugs more safely in the future.   Access this insightful podcast at - https://lnkd.in/ewAmGyxj   #ProteinEngineering #DrugDevelopment #AntibodyTherapeutics #CPHIPodcast #CDMO #CRO

Antibody-drug conjugates (ADCs) are complex biologics that require precise purification to ensure optimal efficacy. Membrane chromatography plays a crucial role in separating the desired product from free payload and undesired conjugate species, effectively refining the composition of ADCs.   Our scientific poster, "Development of an ADC Process with Single Use Membrane Technology," explores how single-use membrane chromatography streamlines purification processes, offering a scalable and efficient solution for ADC process development and manufacturing.   Access the full poster and learn more about advancing your ADC program: https://lnkd.in/eizWYBkK   #ADCs #Bioconjugation #DrugDevelopment #Biologics #SingleUseTechnology #CDMO #GMP